PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics

Vera D'Aloisio; Paolo Dognini; Gillian A Hutcheon; Christopher R Coxon

doi:10.1016/j.drudis.2021.02.019

PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics

Drug Discov Today. 2021 Jun;26(6):1409-1419. doi: 10.1016/j.drudis.2021.02.019. Epub 2021 Feb 26.

Authors

Vera D'Aloisio¹, Paolo Dognini¹, Gillian A Hutcheon¹, Christopher R Coxon²

Affiliations

¹ School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool L3 3AF, UK.
² Institute of Chemical Sciences, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK. Electronic address: c.coxon@hw.ac.uk.

PMID: 33647438
DOI: 10.1016/j.drudis.2021.02.019

Abstract

As of 2020, there were >100 approved peptides with therapeutic or diagnostic applications. However, a complete database providing information on marketed peptides is not freely available, making the peptide chemists' job of designing future peptide drug candidates challenging. Unlike the rules for small-molecule drugs, there is no general set of guidelines for designing a successful peptide-based drug. In this review, together with our freely available database (PepTherDia, http://peptherdia.herokuapp.com), we provide insights into what a successful peptide therapeutic or diagnostic agent looks like and lay the foundation for establishing a set of rules to help future medicinal chemists to design peptide candidates with increased approval rates.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Chemistry, Pharmaceutical / methods
Databases, Factual*
Drug Approval
Drug Design*
Humans
Peptides / administration & dosage*
Peptides / chemistry
Peptides / pharmacology

Substances

Peptides